Consensus Q2 2026 revenue is pegged at $362.4 million with an EPS of $1.11, while the stock currently trades at $102.64, trailing the average analyst price target of $112.75.
Investors are primarily focused on the strategic details and regulatory implications of the recently announced definitive merger agreement with Curium, a deal set to reshape the company's radiopharmaceutical leadership.
The report comes at a critical juncture as the company navigates intensifying competition and pricing pressure on its flagship imaging agent, Pylarify. Management is expected to provide updates on the commercial transition to Pylarify TruVu and progress within its radiotherapeutic pipeline following recent FDA feedback.